Skip to content

A randomized, double blind, placebo-controlled trial on the effect of rosiglitazone in reversing newly diagnosed type 2 diabetes to non-diabetic status

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN76036162
Enrollment
80
Registered
2006-02-28
Start date
2003-09-09
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus (type 2) Urological and Genital Diseases Diabetes mellitus (type 2)

Interventions

Primary intervention: rosiglitazone versus placebo for 52 weeks Secondary intervention: standard lifestyle modification advice

Sponsors

Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetic patients above 18 years of age 2. Newly diagnosed diabetes within one year with HbA1c <7% at the time of entry to the study 3. No history of exposure to any anti-diabetic medications except diet control or insulin during period of gestational diabetes 4. Alcohol consumption less than 50 g/day

Exclusion criteria

Exclusion criteria: 1. Significantly impaired renal function with plasma creatinine >200 mmol/l 2. Known case of liver cirrhosis (Child’s B grading or above) or significantly impaired liver function (alanine aminotransferase [ALT] or aspartate aminotransferase [AST], greater than two times the upper limit of normal) 3. Congestive heart failure of class III or IV by the New York Heart Association classification (NYHA) 4. Progressive fatal disease 5. History of drug or alcohol abuse 6. History of hypersensitivity to study medication or drugs with similar chemical structure to rosiglitazone 7. Pregnant women or those planning a pregnancy 8. Lactation 9. Known severe non-compliance to medication or any factor, which will affect the completion of the study as judged by the investigator 10. Need of any medication, which will affect interpretation of Oral Glucose Tolerance Test (OGTT) such as regular oral steroid or episodic high dose steroid

Design outcomes

Primary

MeasureTime frame
Glycaemic status as assessed by 75 g OGTT at 52 weeks

Secondary

MeasureTime frame
1. Change of insulin resistance and insulin reserve as assessed by Homeostasis Model Assessment (HOMA) at 52 weeks 2. Cardiovascular risk factors assessed at 52 weeks 3. Treatment effect 13 weeks after treatment stopped

Countries

Hong Kong

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026